{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:29:50Z","timestamp":1772087390986,"version":"3.50.1"},"reference-count":68,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["514598620"],"award-info":[{"award-number":["514598620"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>NUT carcinoma (NC) is a rare exceptionally aggressive malignancy, defined by NUTM1 gene translocations, most commonly generating a BRD4::NUTM1 fusion that results in a poor prognosis and limited therapeutic options. Oncolytic virotherapy has emerged as a promising strategy for NC, and the dual bromodomain and extra-terminal domain (BET) and p300\/CBP inhibitor NEO2734 has demonstrated potent antiproliferative activity. To investigate multimodal therapeutic approaches that combine epigenetic modulation with immunogenic and cytotoxic effects of oncolytic viruses (OVs), we evaluated two recombinant OVs, including the herpes simplex virus talimogene laherparepvec (T-VEC) and a measles vaccine virus (MeV-GFP), in combination with NEO2734 in four distinct NC cell lines. Viability assays revealed enhanced tumor cell reduction with all combinations, including synergistic effects with T-VEC combinations. Cell cycle analysis showed G1 arrest with NEO2734 alone, whereas its combination with T-VEC resulted in S-phase broadening and reduced G2-phase populations, consistent with replicative stress and increased cytotoxicity. Evaluation of immunogenic cell death (ICD) markers displayed elevated ATP and HMGB1 levels and increased surface calreticulin with T-VEC and NEO2734 combinations. Overall, these findings indicate that combining OVs with BET\/p300 inhibitors elicits potent antitumor responses, supports synergistic interactions and immunogenicity, and warrants further investigation in multimodal therapeutic strategies for NC.<\/jats:p>","DOI":"10.3390\/v18020267","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:00:52Z","timestamp":1771840852000},"page":"267","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced Antitumor Activity and Induction of Immunogenic Cell Death in NUT Carcinoma Cells by Combining Oncolytic Viruses with the Dual Inhibitor NEO2734"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3119-423X","authenticated-orcid":false,"given":"Fiona D.","family":"Nitschke","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6884-8249","authenticated-orcid":false,"given":"Julia","family":"Beil","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"},{"name":"National Center for Tumor Diseases (NCT), NCT T\u00fcbingen, a Partnership Between DKFZ and Department of Medical Oncology and Pneumology, Medical University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Smirnow","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Schenk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3640","authenticated-orcid":false,"given":"Mary E.","family":"Carter","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"},{"name":"National Center for Tumor Diseases (NCT), NCT T\u00fcbingen, a Partnership Between DKFZ and Department of Medical Oncology and Pneumology, Medical University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4557-7730","authenticated-orcid":false,"given":"Ulrich M.","family":"Lauer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"},{"name":"National Center for Tumor Diseases (NCT), NCT T\u00fcbingen, a Partnership Between DKFZ and Department of Medical Oncology and Pneumology, Medical University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6709-9135","authenticated-orcid":false,"given":"Linus D.","family":"Kloker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"},{"name":"National Center for Tumor Diseases (NCT), NCT T\u00fcbingen, a Partnership Between DKFZ and Department of Medical Oncology and Pneumology, Medical University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/pin.12727","article-title":"NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment","volume":"68","author":"French","year":"2018","journal-title":"Pathol. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/cncy.21761","article-title":"Cytopathologic features of NUT midline carcinoma: A series of 26 specimens from 13 patients","volume":"124","author":"Bishop","year":"2016","journal-title":"Cancer Cytopathol."},{"key":"ref_3","first-page":"304","article-title":"BRD4-NUT fusion oncogene: A novel mechanism in aggressive carcinoma","volume":"63","author":"French","year":"2003","journal-title":"Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"pkz094","DOI":"10.1093\/jncics\/pkz094","article-title":"An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients","volume":"4","author":"Chau","year":"2020","journal-title":"JNCI Cancer Spectr."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Moreno, V., Saluja, K., and Pina-Oviedo, S. (2022). NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.860830"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/sj.onc.1210852","article-title":"BRD-NUT oncoproteins: A family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells","volume":"27","author":"French","year":"2008","journal-title":"Oncogene"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/2159-8290.CD-14-0014","article-title":"NSD3-NUT fusion oncoprotein in NUT midline carcinoma: Implications for a novel oncogenic mechanism","volume":"4","author":"French","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.molcel.2021.03.008","article-title":"Enhancers are activated by p300\/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release","volume":"81","author":"Narita","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1038\/emboj.2010.176","article-title":"Oncogenesis by sequestration of CBP\/p300 in transcriptionally inactive hyperacetylated chromatin domains","volume":"29","author":"Reynoird","year":"2010","journal-title":"EMBO J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-pathol-011811-132438","article-title":"Pathogenesis of NUT midline carcinoma","volume":"7","author":"French","year":"2012","journal-title":"Annu. Rev. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-22-0591","article-title":"Report of the First International Symposium on NUT Carcinoma","volume":"28","author":"French","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/s41388-020-01625-0","article-title":"Supercharging BRD4 with NUT in carcinoma","volume":"40","author":"Eagen","year":"2021","journal-title":"Oncogene"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1101\/gad.267583.115","article-title":"The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains","volume":"29","author":"Alekseyenko","year":"2015","journal-title":"Genes Dev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.bulcan.2022.01.015","article-title":"NUT carcinoma in children, adolescents and young adults","volume":"109","author":"Lemelle","year":"2022","journal-title":"Bull. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/cncr.30242","article-title":"Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck","volume":"122","author":"Chau","year":"2016","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"You, Y., Lu, S., Sun, F., He, X., Wang, J., Huang, J., Que, Y., Zhen, Z., Zhang, Y., and Zhu, J. (2025). Pediatric NUT carcinoma: A patient series and literature review. BMC Pediatr., 25.","DOI":"10.1186\/s12887-025-06278-0"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/bjc.2014.54","article-title":"Comparative drug screening in NUT midline carcinoma","volume":"110","author":"Beesley","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1158\/1078-0432.CCR-12-1153","article-title":"Clinicopathologic features and long-term outcomes of NUT midline carcinoma","volume":"18","author":"Bauer","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yang, G., Liu, R., Yang, L., Yang, X., Tang, X., and Mao, H. (2025). Pulmonary NUT carcinoma, an elusive and refractory entity, shows transient response to chemotherapeutics and PD-1 inhibitor: A case report and literature review. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1497124"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107496","DOI":"10.1016\/j.lungcan.2024.107496","article-title":"Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients","volume":"189","author":"Kloker","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41698-024-00768-7","article-title":"Adding checkpoint inhibitors to first-line chemotherapy for NUT carcinoma patients","volume":"9","author":"Haebe","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"101184","DOI":"10.1016\/j.tranon.2021.101184","article-title":"Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors","volume":"14","author":"Riess","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1007\/s00432-023-04621-5","article-title":"Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case","volume":"149","author":"Chen","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Qu, J., Chen, Z., Zhu, Y., Huang, J., and Shen, Q. (2025). Pulmonary Nuclear protein in Testis (NUT) carcinoma: Clinical, molecular characteristics, and treatment strategies. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13593-3"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1158\/1078-0432.CCR-25-1071","article-title":"Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry","volume":"31","author":"Kim","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"201068","DOI":"10.1016\/j.omton.2025.201068","article-title":"Targeting oncogenic fusion-driven NUT carcinoma with CRISPR-Cas9 genome editing","volume":"33","author":"Carle","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4143\/crt.2022.910","article-title":"Cancer-Specific Sequences in the Diagnosis and Treatment of NUT Carcinoma","volume":"55","author":"Lee","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1158\/0008-5472.CAN-21-0649","article-title":"miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4","volume":"81","author":"Gen","year":"2021","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lauer, U.M., Hinterleitner, M., Horger, M., Ohnesorge, P.V., and Zender, L. (2022). NUT Carcinoma-An Underdiagnosed Malignancy. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.914031"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/oncolo\/oyad177","article-title":"Prolonged Survival of NUT Midline Carcinoma and Current Approaches to Treatment","volume":"28","author":"Kaplan","year":"2023","journal-title":"Oncologist"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.21037\/tcr-20-1884","article-title":"Advances in the pathogenesis and treatment of nut carcinoma: A narrative review","volume":"9","author":"Wang","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/ijc.33861","article-title":"Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I\/II open-label, dose escalation study","volume":"150","author":"Cousin","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41416-020-01180-1","article-title":"A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma","volume":"124","author":"Shapiro","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2021.01.018","article-title":"Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE","volume":"146","author":"Pearson","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1158\/0008-5472.CAN-23-1475","article-title":"EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes","volume":"83","author":"Huang","year":"2023","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/1535-7163.MCT-20-0087","article-title":"Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734","volume":"19","author":"Knox","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lauer, U.M., and Beil, J. (2022). Oncolytic viruses: Challenges and considerations in an evolving clinical landscape. Future Oncol.","DOI":"10.2217\/fon-2022-0440"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.trecan.2015.10.004","article-title":"Oncolytic Viruses: Exploiting Cancer\u2019s Deal with the Devil","volume":"1","author":"Pikor","year":"2015","journal-title":"Trends Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Palanivelu, L., Liu, C.H., and Lin, L.T. (2022). Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1038226"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.ymthe.2025.03.035","article-title":"Oncolytic viruses as cancer therapeutics: From mechanistic insights to clinical translation","volume":"33","author":"Alwithenani","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ohnesorge, P.V., Berchtold, S., Beil, J., Haas, S.A., Smirnow, I., Schenk, A., French, C.A., Luong, N.M., Huang, Y., and Fehrenbacher, B. (2022). Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14112761"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sotiriadis, S., Beil, J., Berchtold, S., Smirnow, I., Schenk, A., and Lauer, U.M. (2024). Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors. Viruses, 16.","DOI":"10.3390\/v16050775"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kloker, L.D., Calukovic, B., Benzler, K., Golf, A., B\u00f6hm, S., G\u00fcnther, S., Horger, M., Haas, S., Berchtold, S., and Beil, J. (2022). Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.995744"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/JVI.02106-12","article-title":"Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis","volume":"87","author":"Berchtold","year":"2013","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Scheubeck, G., Berchtold, S., Smirnow, I., Schenk, A., Beil, J., and Lauer, U.M. (2019). Starvation-Induced Differential Virotherapy Using an Oncolytic Measles Vaccine Virus. Viruses, 11.","DOI":"10.3390\/v11070614"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Carter, M.E., Hartkopf, A.D., Wagner, A., Volmer, L.L., Brucker, S.Y., Berchtold, S., Lauer, U.M., and Koch, A. (2022). A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.826302"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/21645515.2017.1412896","article-title":"Talimogene laherparepvec: First in class oncolytic virotherapy","volume":"14","author":"Conry","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_51","unstructured":"(2025, November 06). CellTiter-Glo\u00ae Luminescent Cell Viability Assay. Available online: https:\/\/www.promega.de\/products\/cell-health-assays\/cell-viability-and-cytotoxicity-assays\/celltiter_glo-luminescent-cell-viability-assay\/?catNum=G7571."},{"key":"ref_52","unstructured":"(2025, November 06). Lumit\u00ae HMGB1 (Human\/Mouse) Immunoassay. Available online: https:\/\/www.promega.de\/en\/products\/cell-health-assays\/inflammation-assay\/lumit-hmgb1-human-mouse-immunoassay\/?catNum=W6110."},{"key":"ref_53","first-page":"1","article-title":"Quantitation of calreticulin exposure associated with immunogenic cell death","volume":"632","author":"Liu","year":"2020","journal-title":"Methods Enzymol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/ejh.13525","article-title":"Targeting both BET and CBP\/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma","volume":"106","author":"Ryan","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1182\/bloodadvances.2020001879","article-title":"Antitumor activity of the dual BET and CBP\/EP300 inhibitor NEO2734","volume":"4","author":"Spriano","year":"2020","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Spiesschaert, B., Angerer, K., Park, J., and Wollmann, G. (2021). Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits. Cancers, 13.","DOI":"10.3390\/cancers13143386"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Chianese, A., Santella, B., Ambrosino, A., Stelitano, D., Rinaldi, L., Galdiero, M., Zannella, C., and Franci, G. (2021). Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13112761"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-4939-0888-2_10","article-title":"Cell cycle regulation during viral infection","volume":"1170","author":"Bagga","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Nickoloff, J.A., Jaiswal, A.S., Sharma, N., Williamson, E.A., Tran, M.T., Arris, D., Yang, M., and Hromas, R. (2023). Cellular Responses to Widespread DNA Replication Stress. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316903"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/bs.apcsb.2022.11.013","article-title":"Mechanism of cell cycle regulation and cell proliferation during human viral infection","volume":"135","author":"Panda","year":"2023","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1080\/15384101.2018.1426415","article-title":"Simple discrimination of sub-cycling cells by propidium iodide flow cytometric assay in Jurkat cell samples with extensive DNA fragmentation","volume":"17","author":"Babes","year":"2018","journal-title":"Cell Cycle"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1182\/blood-2016-08-731737","article-title":"Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients","volume":"128","author":"Fucikova","year":"2016","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Sun, Y., Han, J., Wang, Z., Li, X., Sun, Y., and Hu, Z. (2020). Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.621093"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1158\/0008-5472.CAN-23-2545","article-title":"The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma","volume":"83","author":"Durall","year":"2023","journal-title":"Cancer Res."},{"key":"ref_68","unstructured":"(2026, January 12). BioRender.com. Available online: https:\/\/www.biorender.com."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/267\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:14:02Z","timestamp":1772082842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":68,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["v18020267"],"URL":"https:\/\/doi.org\/10.3390\/v18020267","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]}}}